X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs VENUS REMEDIES - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES VENUS REMEDIES DIVIS LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x 38.4 -4.1 - View Chart
P/BV x 6.2 0.2 4,118.6% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DIVIS LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
VENUS REMEDIES
Mar-18
DIVIS LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,142126 906.9%   
Low Rs53361 872.5%   
Sales per share (Unadj.) Rs146.6301.8 48.6%  
Earnings per share (Unadj.) Rs33.0-24.9 -132.8%  
Cash flow per share (Unadj.) Rs38.42.5 1,509.2%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs222.8293.3 76.0%  
Shares outstanding (eoy) m265.4712.34 2,151.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.70.3 1,844.0%   
Avg P/E ratio x25.3-3.8 -674.3%  
P/CF ratio (eoy) x21.836.7 59.3%  
Price / Book Value ratio x3.80.3 1,178.8%  
Dividend payout %30.30-   
Avg Mkt Cap Rs m222,3181,154 19,268.5%   
No. of employees `00010.80.9 1,163.5%   
Total wages/salary Rs m4,561393 1,160.2%   
Avg. sales/employee Rs Th3,616.04,026.1 89.8%   
Avg. wages/employee Rs Th423.8425.0 99.7%   
Avg. net profit/employee Rs Th814.9-331.8 -245.6%   
INCOME DATA
Net Sales Rs m38,9153,724 1,044.9%  
Other income Rs m1,13423 5,041.8%   
Total revenues Rs m40,0493,747 1,069.0%   
Gross profit Rs m12,617395 3,195.8%  
Depreciation Rs m1,425338 421.2%   
Interest Rs m13354 3.8%   
Profit before tax Rs m12,313-275 -4,472.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,54332 11,212.7%   
Profit after tax Rs m8,770-307 -2,857.6%  
Gross profit margin %32.410.6 305.8%  
Effective tax rate %28.8-11.5 -250.7%   
Net profit margin %22.5-8.2 -273.5%  
BALANCE SHEET DATA
Current assets Rs m45,3512,638 1,719.4%   
Current liabilities Rs m6,5072,305 282.4%   
Net working cap to sales %99.88.9 1,116.2%  
Current ratio x7.01.1 608.9%  
Inventory Days Days127135 93.5%  
Debtors Days Days9546 205.4%  
Net fixed assets Rs m21,1604,871 434.4%   
Share capital Rs m531123 430.2%   
"Free" reserves Rs m58,6253,496 1,677.1%   
Net worth Rs m59,1563,619 1,634.5%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m67,8327,509 903.4%  
Interest coverage x926.80.2 415,657.6%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.5 115.7%   
Return on assets %12.90.6 2,051.2%  
Return on equity %14.8-8.5 -174.8%  
Return on capital %20.81.6 1,317.1%  
Exports to sales %00-   
Imports to sales %21.813.9 157.2%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485517 1,642.7%   
Fx inflow Rs m32,3590-   
Fx outflow Rs m9,042517 1,750.7%   
Net fx Rs m23,317-517 -4,514.4%   
CASH FLOW
From Operations Rs m7,759514 1,508.3%  
From Investments Rs m-4,783-123 3,885.5%  
From Financial Activity Rs m-3,142-387 811.6%  
Net Cashflow Rs m-1664 -3,952.4%  

Share Holding

Indian Promoters % 52.0 32.9 158.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.2 6,555.6%  
FIIs % 19.0 0.6 3,275.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 66.4 25.9%  
Shareholders   31,796 20,121 158.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUN PHARMA  MERCK LTD  NOVARTIS  J.B.CHEMICALS  DR. REDDYS LAB  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 25, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS